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Abstract
Multivariate equivalence testing becomes necessary whenever the similarity rather than
a difference between several treatment groups with multiple endpoints has to be shown.
This problem occurs in various applications, including bioequivalence or the comparison
of dissolution profiles. Therefore, several tests have been suggested during the last decade
for the assessment of multivariate equivalence. Recently Munk & Pflu¨ger (1999) proposed
to test ellipsoidal instead of rectangular hypotheses as it is current practice in many ap-
plications. In this paper we provide several asymptotic tests for ellipsoidal equivalence
which are compared numerically with competitors suggested by Brown, Cassella & Hwang
(1995) and Munk & Pflu¨ger (1999). We find that the proposed tests are superior (up to
90%) to both tests with respect to power. In addition, a simulation study reveals the sug-
gested tests as robust against violation of normality. These tests are very simple to apply,
because inversion of confidence regions is avoided. Asymptotic formulas for the power
function and sample size determination are given. Finally, all procedures are compared
in two data examples.
1
keywords and phrases: hypotheses testing, multivariate bioequivalence, multiple end-
points, confidence inclusion rules, equivalence, Hotelling’s T 2 test, equivariance, boot-
strap, quadratic forms, power function.
1 Introduction
Recently, testing of multivariate equivalence hypotheses has become a field of certain
interest, mainly motivated by the problem of assessing multivariate bioequivalence, i.e. the
assessment of a similar rate and extend of absorption in the blood circulation (cf. Chow
& Liu (1992) for a survey) of several pharmacokinetic characteristics of two different
formulations of a drug. We refer to Brown, Cassella & Hwang (1995), Hsu, Lu
& Chan (1995), Chinchilli & Elswick (1997) or Wang, DasGupta & Hwang
(1999) for a discussion and several tests for the multivariate bioequivalence problem.
However, the multivariate equivalence problem is not solely restricted to bioequivalence
assessment as the following example from neurophysiology shows. For further applications
in environmental or managerial science cf. Erickson & McDonald (1995), Dixon
(1998) or McBride (1999).
Example 1. Exteroceptive suppression (cf. Schoenen (1993)), ES, of temporalis mus-
cle activity is the electrophysiological correlate of the jaw-opening reflex. ES consists
itself in two further components ESM and ESP, the monosynaptic and polysynaptic sup-
pression. Steinhoff et al. (1996) investigated the influence of epilepsy on ES in a
study with 20 healthy volunteers and 31 patients with epilepsy. The conjecture, that ES
could be possibly influenced by epilepsy was essentially based on the observation that
Parkinson’s disease and chronic headache seem to cause an effect on ES (Nakashima
et al. (1990)). This analogy, however, was never based on solid physiological grounds.
Therefore, it was the aim of Steinhoff et al.’s (1996) study to show that this con-
jecture cannot be supported by the data. To this end several two sided t tests for the
null hypotheses of no difference were performed, each resulting in p-values larger than
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0.8. However, this does not imply the rigorous assessment of similarity at a controlled
error rate between the control and epileptic group as pointed out by Steinhoff et al.
(1996). An explorative data analysis suggests to assume a bivariate (ESM, ESP) normal
model with the same covariance structure for the epileptic (E) and control group (C),
respectively (cf. Munk & Pflu¨ger (1999) for the raw data)
Xij ∼ N2(θi, Σ˜) i = C,E and j = 1, . . . , ni with nC = 19, nE = 31.
The following (with pooled variance estimator for the ESP and ESM values, respectively)
estimators for the mean difference and covariance matrix are obtained
X := X¯C − X¯E =

 −0.0586
−0.3325

 and Σˆ =

 0.8526 0.0188
0.0188 1.3525

 .
In the following we present tests in order to assess that there is no ’relevant difference’
of the means between the reference group and the epilepsy group, for ESM and ESP ,
respectively. Hence, it follows that ES is not an appropriate diagnostic tool for epilepsy
or the success of a particular therapeutic method as conjectured by Steinhoff et al.
(1996). To this end it is required to show at a controlled error rate that θE ≈ θC .
According to various definitions of similarity several tests for multivariate equivalence
were suggested in the literature during the last 5 years. Most of these tests are designed
for rectangular hypotheses under a normal assumption (cf. Berger (1982), Berger &
Hsu (1996), Roy (1996) or Wang, DasGupta & Hwang (1999)). These authors
provide several tests in order to assess that a multivariate mean θ = (θ1, . . . , θp) ∈ Rp is
contained in a hyperrectangle, i.e. for the hypotheses
H : θ ∈ ΘH = {θ : ∃i : |θi| > ∆} vs. K : θ ∈ ΘK = {θ : max
i=1,...,p
|θi| ≤ ∆}. (1)
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The most popular tests for (1) are based on the intersection union principle applied to
confidence interval inclusion rules (Berger & Hsu (1996)). These tests are simple
to perform and well established in applications. They may have the disadvantage to be
rather conservative (resulting in a low power) when the number of endpoints p increases
as pointed out by Hwang (1996) and Munk & Pflu¨ger (1999). The definition
of equivalence in terms of the maximum norm is, of course, not the only possibility
to formalize similarity. Therefore, Munk & Pflu¨ger (1999) suggested to consider
ellipsoidal hypotheses
H : θ′Aθ > ∆ vs. K : θ′Aθ ≤ ∆, (2)
for a positive defintite matrix A > 0. This is, e.g., in accordance with a measure of
equivalence recommended by the FDA (1997) for testing equivalence of dissolution pro-
files, i.e. the proportion of a tablet dissolved against time. For a discussion of recent
methodology in dissolution profile testing we refer to O’Hara et al. (1997), Shah et
al. (1998) or Sierra-Cavazos & Berger (1999). Because these hypotheses cannot
be represented as the intersection resp. union of several one-dimensional hypotheses the
intersection union principle (cf. Berger & Hsu (1996)) or related methods cannot be
applied and different testing methodology is required. Here, the general testing princi-
ple of Aitchison (1964) by inverting 1 − α confidence regions is applicable. This leads,
however, in general to very conservative tests (Munk (1994), Berger & Hsu (1996)).
For general hypotheses this technique was improved by Brown et al. (1995) and for
convex alternatives by Munk & Pflu¨ger (1999).
This paper is organized as follows. In Section 2 we state the precise model for the test. In
Section 3 we review on existing methods for the assessment of multivariate equivalence and
discuss various new tests for the hypotheses (2). Our approach is based on the asymptotic
normality of the centered quadratic form X ′AX − θ′Aθ (after normalizing by the sample
size). In Section 4 we present the results of a Monte Carlo study on size and power which
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shows that the normal approximation yields rather liberal tests, i.e. the nominal level is
exceeded. In order to improve the accuracy of the normal approximation several finite
sample approximations are investigated including various Box - type χ2 approximations
and bootstrap tests. We found that the bias corrected accelerated boostrap method
(Efron & Tibshirani, 1993) represents a good compromise between a very powerful
method and a method which maintains its nominal level with high accuracy. In particular,
differences in power up to 90% compared to Brown, Casella & Hwang’s (1995) and
Munk & Pflu¨ger’s (1999) test were observed. Furthermore, simulations show that
the new test is very robust against violation of normality.
Finally, in Section 5 we compare all methods by reanalyzing the data set in Example 1
and an example from Chinchilli & Elswick (1997), who investigated the multivariate
bioequivalence of two different formulations of Ibuprofen.
The paper closes with a discussion and summary section where also formulae for comput-
ing sample size and power are given.
2 Model and testing problem
We restrict ourselves for the moment to i.i.d. observations coming from a normal model.
Generalizations to the two sample comparison and other designs will be discussed later.
We mention also that our results are asymptotically valid under very weak assumptions
on the error distribution which is in contrast to existing methods for testing multivariate
equivalence. This will be made precise in the next section.
Let throughout the followingX1, · · · , Xn ∼ Np(θ, Σ˜) independent random variables, which
follow a p-variate normal distribution with mean θ ∈ Rp and covariance Σ˜ ∈ Rp×p which is
assumed to be positive definite, Σ˜ > 0. Sufficient statistics are the mean 1
n
∑n
i=1Xi =: X
and the covariance estimator Σˆ = 1
n
∑n
i=1(Xi−X)(Xi−X)t. It follows that X ∼ Np(θ,Σ),
and Σˆ ∼ Wd(Σ) (here Σ = 1nΣ˜ and d = n − 1 ≥ p) are independently distributed
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according to a multivariate normal distribution with unknown mean θ ∈ Rp and unknown
covariance structure Σ and a Wishart distribution with d degrees of freedom, respectively
(Anderson (1984)). Throughout the following we may consider w.l.o.g. instead of the
testing problem in (2) the standardized problem
H : θtθ > 1 vs. K : θtθ ≤ 1. (3)
This can be achieved in (2) for any A > 0 by a transformation of the data Xi into
X∗i =
1√
∆
A
1
2Xi (4)
because A > 0 allows a unique decomposition as A
1
2A
1
2 = A, A1/2 a symmetric matrix.
In order to keep notation simple we will write in the following Xi instead of X
∗
i .
Before we consider the construction of several tests for (3), we find it pertinent to recall
briefly the discussion in (Munk & Pflu¨ger (1999)) concerning the choice of ellipsoidal
hypotheses instead of rectangular hypotheses as in (1). In most applications θ will be
the difference of two means θ = θ1 − θ2 which have to be shown to be equivalent (cf.
Example 1). For example, drug authorities, such as the FDA, currently require that
in a single dose bioequivalence study of oral drug formulation average bioequivalence is
shown with respect to both, AUC and Cmax. We mention that the criterion of aver-
age bioequivalence which focuses on the comparison of means solely, has been criticised
by various authors (cf. Hauck & Anderson (1992) or Schall (1995) among many
others) and different bioequivalence criteria (various types of population and individ-
ual bioequivalence) have been suggested. This is highlighted in a recent draft guidance
for industry entitled ”Average, Population and Individual Approaches to Establishing
Bioequivalence” (U.S. Dep. of Health and Human Services, Food and Drug
Administration, CDER, Rockville, MD (1999)). In the present paper, however,
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we focus only on average bioequivalence, simply denoted as bioequivalence. According to
the FDA guidance, bioequivalence may be claimed if every univariate comparison of the
pharmacokinatic parameters AUC, Tmax, or Cmax allows one to declare bioequivalence
at level of significance α = 0.05 (e.g. Guidance for Industry: In Vivo Pharma-
cokinetics and Bioavailability Studies and in Vitro Dissolution Testing
for Levothyroxine Sodium Tablets, U.S. Department of Health and Hu-
man Services, CDER (1999)). To our knowledge up to now all approaches focus on
hypotheses as in (1), i.e. bioequivalence is declared if each of the components of the
difference of the mean vector is close to zero. We believe, however, that often the con-
sideration of quadratic forms QA(θ) = θ
tAθ as a distance measure is more appropriate
(cf. Munk & Pflu¨ger (1999) for a discussion). Here the region of equivalence is the
ellipsoid Q∆ = {θ : QA(θ) ≤ ∆} where ∆ denotes a fixed tolerance bound (cf. Figure 1).
Γ
Q
∆
∆
∆
1
2
C
AUC
max
Figure 0: Ellipsoidal (Q∆) and rectangular hypotheses (Γ) in the case p = 2
Interestingly, for the anaylsis of dissolution profiles, the FDA (1997), recommends ellip-
soidal hypotheses completely analogous to (3). Methods for this problem are discussed
in Moore & Flanner (1996), O’Hara et al. (1997) and Shah, Tsong, Sathe
& Mia (1998). For example, the f2 method proposed in Moore & Flanner (1996)
requires weights ωk which corresponds to the eigenvalues of the matrix A in (2). Ma
et al. (2000) performed a simulation study for bootstrapping the f2-statistic with the
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percentile method and found quite reasonable performance of the resulting test.
3 Tests
In this Section we will discuss several testing procedures for the multivariate equivalence
problem (3). This includes tests already suggested in the literature and various new tests.
We restrict our representation to the case of an i.i.d. sample X1, · · · , Xn. Generalizations
to the two sample comparison with independent samples, such as required in Example 1,
are straight forward and discussed in Example 1 in Section 5.
3.1 Confidence inclusion rules
A classical principle due to Aitchison (1964) states that for any confidence set C1−α(X, Σˆ)
for θ at level 1− α the region
A(ΘH) = {X : ΘH ∩ C1−α(X, Σˆ) 6= ∅}
defines the acceptance region of a test for H : θ ∈ ΘH against K : θ ∈ ΘK , ΘH∩ΘK = ∅,
at level α because
Pθ(θ /∈ C1−α(X, Σˆ)) ≤ α.
Hence, if ΘK := {θ ∈ Rp : θtθ ≤ 1}, the p-dimensional sphere, the following rule
constitutes a test at level α for the hypothesis (3):
ψα(X, Σˆ)) =

 1 : C1−α(X, Σˆ) ⊂ ΓK0 : else .
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Munk & Pflu¨ger (1999) showed, that if the confidence set obeys certain equivariance
properties and the alternative K is convex (which is, of course, the case in the present
setting) it is possible to improve Aitchison’s (1964) result because then the resulting
level of the test is α/2. The level α/2 is sharp, i.e. it cannot be improved in general. This
leads to the following test which results from inverting Hotelling’s confidence set.
3.1.1 Hotelling’s T 2confidence set
In a first step we invert Hotelling’s T 2 test (cf. Anderson, (1984)) for H : θ = θ0
with test statistic
T 2θ0 := d(X − θ0)tΣˆ−1(X − θ0) (5)
which yields the (1− α) confidence set
CT
2
1−α := {θ0 : T 2θ0 ≤ f 2α,p,d}, (6)
where f 2α,p,d =
dp
d−p+1
F−1p,d−p+1(α) and Fµ,ν denotes a central F -distribution with µ and ν
degrees of freedom. Theorem 2.1 in Munk & Pflu¨ger (1999) yields that
ψT
2
α (X, Σˆ) =

 1 : C
T 2
1−2α(X, Σˆ) ⊂ ΘK
0 : else
constitutes a test at level α. Observe, that the confidence region required for the test ψT
2
α
has confidence coefficient 1− 2α and not 1− α.
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3.1.2 Brown-Casella-Hwang’s confidence set
Another candidate for the confidence inclusion rule is the confidence set constructed by
Brown et al. (1995). The reasoning behind their approach is to minimise the expected
volume at a preassigned parameter point θ0, which can be assumed w.l.o.g. as θ0 = 0.
Originally, this confidence set was constructed for the case of know variance Σ, resulting
in the confidence set
CBCH1−α (X,Σ) := {θ : (θtΣ−1θ)
1
2 ≤ z1−α + XΣ
−1θ
(θtΣ−1θ)
1
2
},
where z1−α is the upper α quantile from a univariate standard normal distribution. For
the case of unknown covariance we will throughout the following simply replace Σ by the
estimator 1
n
Σˆ. Hence denote
ψBCHα (X, Σˆ) =

 1 : C
BCH
1−α (X,
1
n
Σˆ) ⊂ ΘK
0 : else
as the according equivalence test. Note, that the BCH-confidence set does not share the
equivariance property (like the Hotelling’s T2 confidence set) required for application of
Munk & Pflu¨gers (1999) Theorem 2.1 and hence the 1− 2α-adjustment is not valid.
Other confidence regions and generalizations of this approach to nonnormal errors can be
found in DasGupta, Gosh & Zen (1995), Wang, DasGupta & Hwang (1999) or
Roy (1996).
3.2 Testing with quadratic forms
3.2.1 The δ-method
The most direct way to construct a test for (3) is to estimate in a first step θtθ by
||X||2p = X tX and then reject the hypothesis for ||X||2p too small. The main difficulty
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encountered with this approach is the effective determination of the distribution of ||X||2p.
Observe, that (cf. Mathai & Provost (1992))
||X||2p D=
p∑
j=1
λj(Uj + bj)
2 (7)
equals in distribution a sum of weighted noncentral χ21 random variables where Uj ∼
N1(0, 1) are i.i.d., j = 1, . . . , p. The weights λj, j = 1, · · · , p, are the eigenvalues of Σ and
b = (b1, · · · , bd)t =
(
1√
n
P tΣ
1
2 θ
)t
, (8)
where P denotes an orthogonal matrix such that 1
n
P tΣ˜P = diag(λ1, . . . , λp). Here
diag(λ1, . . . , λp) denotes a p× p diagonal matrix with diagonal elements λ1, . . . , λp. This
representation highlights the difficulty to determine the exact distribution of ||X||2p be-
cause particularly the estimation of the eigenvalues of Σ causes serious problems. There-
fore, we investigate in the following various approximations of the distribution of ||X||2p.
The simplest method of approximation is the C.L.T.
Theorem 1. Let X1, · · · , Xn ∼ F be an i.i.d. sample from a p-variate distribution F , s.t.
EX1 = θ ∈ Rp, Σ˜ = Cov[X1] > 0 and E||X1||2p < ∞. Then we have for any consistent
estimator Σˆ of the covariance Σ˜
T δn :=
√
n
X tX − θtθ√
4X tΣˆX
D
=⇒ N(0, 1) for θ 6= 0, as n→∞.
Proof. Apply the δ-method and the multivariate C.L.T. (cf. Serfling (1980)) in order to
conclude that
√
n(X tX − θtθ) D=⇒ N(0, 4θtΣ˜θ) for θ 6= 0.
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Observe, that from Kolmogorov’s strong law of large numbers it follows that X tΣˆX
a.s.−→
θtΣ˜θ. Now the assertion follows from Slutzky’s Lemma (Chow & Teicher (1997)).
2
From Theorem 1 we obtain the following asymptotic test
ψδα(X, Σˆ) =

 1 :
√
n(X tX − 1)/
√
4X tΣˆX ≤ zα
0 : else
for the problem (3), where zα denotes the lower α-quantile of the standard normal distri-
bution. In the next section we will demonstrate in a Monte Carlo study that this tests
improves essentially on the power of the confidence region inclusion rules discussed in the
last subsection. However, it turns also out that the normal approximation yields a rather
liberal test (i.e. the nominal level is exceeded) and hence we investigate in the following
various finite sample approximations.
Remark 1. In particular, when θ is close to zero, the distribution of T δn is skewed. For
θ = 0 the asymptotic normality in Theorem 1 even fails to hold. Instead, the distribution,
after multiplication by n1/2 once more, is a sum of weighted χ2 distributions (cf. (7)
again). To account for this skewness we used an idea dating back to Box (1954) where
the approximation by a scaled χ2-distribution gχ2f with random degrees of freedom f and
scaling parameter g is suggested. However, simulations for the approach revealed sizes of
up to three times the level for small sample sizes as 10. As a consequence, we refrain from
displaying the results. Increasing the number of fitted moments by using a non-central
χ2-distribution did not show to improve the size.
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3.2.2 The bootstrap
Another option is, of course, to work with bootstrap approximations. The bias corrected
and accelerated bootstrap (BCa) is investigated with
ψbootbcaα (X1, · · · , Xn) =

 1 : (X
∗tX∗)[nboot×α2]+1 ≤ 1
0 : else
where α2 = Ψ(zˆ0 +
Ψ−1(1−α
2
)
1−aˆ(zˆ0+Ψ−1(1−
α
2
))
) with zˆ0 = ]{X∗tX∗≤XtXnboot } and the acceleration aˆ =∑
n
i=1
(ϑi−ϑ·)
2
(
∑
n
i=1
(ϑi−ϑ·)3)
3
2
. Here ϑi is a jackknifed version of X
tX, s.t. Xi omitted. Further ϑ· denotes
the empirical mean of the ϑi’s i = 1, . . . , n and Ψ the c.d.f. of a standard normal r.v..
For more details see Efron & Tibshirani (1993).
Remark 2. Additional to the bias corrected and accelerated bootstrap we used the per-
centile bootstrap (Efron & Tibshirani (1993)). As in the case of the χ2-approximations
we found a sizes for our small sample situation of 10 observations which are clearly - up
two-and-a-half times - above the level. Again, we refrain from displaying the results.
4 Simulation study
In this section we report on a Monte-Carlo study for the testing problem (3) which was
conducted using the random generator of SAS/IML, internal programming language of
the statistical software SAS, Version 6.12 and 8.03. In each scenario 10000 Monte-Carlo
simulations were performed. The nominal level is always chosen as α = 0.05. In our first
scenario 20 bivariate normal random variables were generated where the covariance was
assumed as
Σ˜ =

 18 − 316
− 3
16
17
16

 .
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The power curve was obtained by cubic B-spline interpolation (in the alternative K)
between the grid points

θ : θ =

 θ1
θ2

 =

 i10
0

 , i = 1, . . . , 10

 .
The number of bootstrap replications for the BCa bootstrap was n
boot = 300, respectively.
Power curves for all tests discussed in the last section are shown in Figure 1. Note, that
θ1 = 1 corresponds to the point (1, 0)
t on the boundary of the null hypotheses (3), whereas
smaller values of θ1 are in the alternative of equivalence. If for the BCa bootstrap the
argument of Ψ−1(·) in the calculation of zˆ0 was zero, we have dropped this value. This
occurred in less that 1% of all cases.
Figure 1: Power curves of the δ-method (CRAMTEST), Munk & Pflu¨ger’s (1999) test
(EQUITEST), the Brown et al. (1995) test (BCWTEST), and the BCA bootstrap (BCA-
BOOT) for n = 20, normal error and 10.000 simulations. The nominal level was α = 0.05.
The next simulation study was performed in order to investigate the actual size of all
tests more detailed. Therefore in Figure 2 the actual level of all tests is displayed for the
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following boundary points of the hypothesis H in (3)

θ : θ =

 θ1
θ2

 =

 i10√
1− ( i
10
)2

 , i = −10, . . . , 10

 .
under the same distributional assumptions as in Figure 1. Again cubic B-spline interpo-
lation is used to interpolate between these grid points.
Figure 2: Actual size of the tests where ||θ|| = 1 and θ2 > 0.
15
Σ˜ n T-Hot Brown-CH delta BCa
10 0.0005 0.0000 0.0364 0.0314
 18 − 316
− 3
16
17
16

 20 0.0045 0.0000 0.0405 0.0293
(ρ ≈ −0.50) 50 0.0200 0.0010 0.0431 0.0254
10 0.0144 0.0385 0.0908 0.0505
 12 0
0 1
4

 20 0.033 0.0500 0.0752 0.0382
(ρ = 0) 50 0.0492 0.0486 0.0586 0.0306
10 0.0136 0.0241 0.0984 0.0607
 12 14
1
4
1
2

 20 0.0267 0.026 0.08 0.0409
(ρ = 0.5) 50 0.0507 0.0292 0.1514 0.0332
Table 1: Size of all tests for various correlations and sample sizes where θ′ = (0, 1).
The numerical values can be found in In Table 1 where also additional sample sizes and
covariance structures were investigated.
From these Figures the following results can be drawn: The normal approximation (δ-
method) is anti conservative in some of scenarios investigated. The BCa bootstrap keeps
its nominal level with high accuracy, even under the assumption of strong correlation.
Note, that the actual level of Brown, Casella & Hwang’s (1995) test may fall far
below the nominal level, particularly when negative correlation is present. A similar
observation holds for the test of Munk & Pflu¨ger (1999). As a main conclusion from
Figure 1 we may draw that the BCa bootstrap outperforms all the other competitors,
having reasonable size and power.
In what follows we would like to address briefly some robustness aspects of the above
discussed tests. To this end we considered outcomes generated by two independent (χ2−
16
1)/4 distributions with additive location θ. Note, that the expectation of these r.v.’s is θ
and the variance of each component equals 1
8
which reflects the first normal component
in the previous normal simulation scenario.
In Table 2 we have displayed a selection of numerical values for the boundary point
θ = (0, 1). The corresponding curves of the actual level can be found in Figure 3.
Test T-Hot Brown-CH delta BCa
size 0.1428 0.0334 0.1453 0.0732
Table 2: Size of tests for (χ2 − 1)/4 error
Figure 3: Size of the tests on the boundary of the hypotheses, where ||θ|| = 1 and
θ2 > 0 for (χ
2 − 1)/4 error.
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Figure 4: Power curves of the tests for n = 20, (χ2 − 1)/4 error and 10.000 simulations.
The nominal level was α = 0.05.
In Figure 4 the resulting power functions are displayed. In summary we may draw the
following conclusions. The actual level is drastically exceeded by Munk & Pflu¨ger’s
(1999) test as well as for the δ-method. Brown, Casella & Hwang’s (1995) method
performs rather accurate albeit very conservative for negative values of θ1. In contrast
the BCa method yields a very accurate approximation of the nominal level α = 0.05
over abroad range of θ1 values. The differences in power between the two last named
tests are rather small. Note the the superior power of the other tests does not yield a
fair comparison due to its exceedance of the nominal level. In summary, only Brown,
Casella & Hwang’s (1995) method and the BCa-bootstrap are able to maintain the
given level under skewed errors. Interestingly, the power of the BCH test is significantly
increased by the χ2-error.
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5 Examples
To demonstrate the practical relevance of the proposed methods we reanalyse the epilepsy
data from the Introduction and an example of a multivariate bioavailability study from
Chinchilli & Elswick (1997).
5.1 Example from neurology
In order to transfer the suggested methodology to the situation of Example 1 in the
Introduction we require a generalization of Theorem 1 in Section 3 to the two sample
case.
Theorem 2. Let X1, · · · , Xm ∼ F be an i.i.d. sample from a p-variate distribution F ,
and independently Y1, · · · , Yn ∼ G an i.i.d. sample from a p-variate distribution G, s.t.
EX1−EY1 = θ1− θ2 = θ ∈ Rp, Σ˜1 = Cov[X1], Σ˜2 = Cov[Y1] > 0 and E||X1||2p, E||Y1||2p <
∞. Then we have for X = X¯−Y¯ and Σˆ = (1+λ−1)Σˆ1+(1+λ)Σˆ2 with m/n→ λ ∈ (0,∞),
that
T δ(m,n) :=
√
m+ n(X tX − θtθ)√
4X tΣˆX
D
=⇒ N(0, 1) for θ 6= 0.
Proof. The proof is similar to Theorem 1, where we take into account that
√
m+ n
{
X¯ − Y¯ − θ} D=⇒ (1 + λ−1)1/2Z1 + (1 + λ)1/2Z2 ,
where Z1 and Z2 are independent p-variate normal r.v.s with covariances Σ˜1 and Σ˜2, re-
spectively.
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Observe, that for the case of equal covariances Σ1 = Σ2 (which we have assumed in
this example) the asymptotic variance Σ = (λ + 1)2/λΣ1. Observe further, that a BCa
bootstrap test can be immediately obtained by drawing separately subsamples from the
samples X1, · · · , Xm and Y1, · · · , Yn.
In order to apply the afore mentioned equivalence tests we have to specify a bound ∆. Here
we have chosen 20% of the range of the control group, for ESM and ESP , respectively.
Hence we end up with the testing problem
H :
∥∥∥∥∥∥

 14θESM
1
8
θESP


∥∥∥∥∥∥
2
2
> 1 versus K :
∥∥∥∥∥∥

 14θESM
1
8
θESP


∥∥∥∥∥∥
2
2
≤ 1 .
Test T-Hot Brown-CH delta BCa
p-value 0.0101 0.0045 7.610−9 0.00989
Table 3: p-values for the epilepsy data
We mention that for the inversion of Hotelling’s confidence interval the pooled estimator
Σˆ =
1
n+m− 2
( ∑
i=1,...,n
(Xi − X¯)t(Xi − X¯) +
∑
j=1,...,m
(Yj − Y¯ )t(Yj − Y¯ )
)
has been used where the degrees of freedom of the F -distribution are now 2 and n+m−2.
In summary we find that all tests decide significantly in favour of equivalence.
5.2 Bioequivalence study
The equivalence of availability of Ibuprofen in the blood of two drugs will be reinvestigated
for data presented by Chinchilli & Elswick (1997). Following these authors it is to be
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tested whether the ratio of the expected AUC’s (Area under the Curve) and the expected
Cmax’s (maximal concentration) are between 0.8 and 1.25.
In detail, it is assumed that independent bivariate r.v.’s are observed in a 2× 2 crossover
design without period effects. After a logarithmic transformation it is to assess whether
H1 : |ηTA − ηRA | ≤ log 1.25 and |ηTC − ηRC | ≤ log 1.25 (9)
where η
(·)
A and η
(·)
C denotes the corresponding expectation of logAUC
(·) and logC
(·)
max.
Taking
X1i :=
1
log 1.25
(logAUCTi − logAUCRi ) , X2i :=
1
log 1.25
(logCTmax,i − logCRmax,i)
yields the model from Theorem 1 with p = 2. After dividing the logarithms of raw data
by 1
log 1.25
in order to transform the problem into the standardized form of the hypothesis
in (3) we obtain the following summary statistics
(Mean difference) X¯ =

 −0.121332
0.190746

, (Covariance) Σˆ =

 0.1300518 0.1368549
0.1368549 0.8743755

 .
For the complete data see Chinchilli & Elswick (1997). In our previous notation,
we have θ = (
ηT
A
−ηR
A
log 1.25
,
ηT
C
−ηR
C
log 1.25
). In Table 2 we display the resulting p-values for the hypoth-
esis (3). We find that all tests under consideration lead to a significant rejection of H,
showing bivariate bioequivalence of the two ibuprofen formulations. Note, however, that
the ordering of the p-values nicely reflects the superior power as found in the last section
of the tests based on quadratic forms compared to the inclusion rules.
Test T-Hot BCH delta BCa
p-value 0.00050 0.00021 ≤ 10−15 9.97710−11
Table 4: p-values for the Ibuprofen data.
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6 Further Remarks and Extensions
Remark 3. Some readers may find it unsuitable for many purposes to choose ellipsoidal
hypotheses instead of the more common rectangular ones. Nevertheless, we would like to
mention, that even for the case of testing a hyperrectangle as in (9) our tests for ellipsoidal
alternatives could be used. To this end, the largest sphere within the rectangle has to be
chosen as the alternative (cf. again Figure 0). Throughout the following we have always
chosen ∆ = 1 and p = 2.
In the following we investigate briefly how the ellipsoidal tests behave in comparison to
the intersection union methods if they are used for rectangular hypotheses. Here, the
intersection-union-test (TOST-test) has rejection region
p⋂
i=1

|Xi| < ∆i − t1−α,d
√
Σˆii
α


where Xi denotes the i-th coordinate of X and t1−α,d the 1−α quantile of a t-distribution
with d degrees of freedom.
In Figure 5 the power curves of all tests are displayed under normal error assumption.
As it was expected the IU-test TOST is most powerful due to its property to be exactly
designed for a rectangular hypotheses. Note, that the BCH-test is significantly inferior
with respect to power whereas all the other tests have reasonable power.
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Figure 5: Power curves of the tost procedure (TOST), δ-method (CRAMTEST), Munk
& Pflu¨ger’s (1999) test (EQUITEST), the Brown et al. (1995) test (BCWTEST), and
the BCA bootstrap (BCABOOT) for n = 20, normal error and 10.000 simulations. The
nominal level was α = 0.05.
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Figure 6: Size of the tests on the boundary of the hypotheses, where θ2 = 1 for normal
error.
Figure 7: Power curves of the tests for n = 20, (χ2 − 1)/4 error and 10.000 simulations.
The nominal level was α = 0.05.
In Figure 6 the nominal level is investigated where θ1 ∈ [−1, 1] and θ2 = 1. It can be
seen that again the BCa-test keeps the nominal level albeit rather conservative. The IU-
method has size close to α = 0.05 over the entire range of θ1 values besides those values
of the hypothesis where θ1 is close to -1 or 1.
In Figure 7 and Table 5 a similar scenario is investigated for skewed error. Observe, that
from Table 5 it follows that the IU-method now exceeds the nominal level whereas the
BCa method again keeps the nominal level rather accurate.
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Test TOST T-Hot Brown-CH delta BCa
size 0.1330 0.1390 0.0379 0.1516 0.0702
Table 5: Size of tests for (χ2 − 1)/4 error
We mention that further simulations have shown (not displayed) that for increasing di-
mension p the difference in power between both tests becomes smaller. When p = 10, the
power of the BCa test is nearly the same as for the IU-method.
Remark 4. In practical applications often it is important to determine the required sam-
ple size to achieve a preassigned power of the asymptotic tests for ellipsoidal hypotheses.
We will assume that X1, · · · , Xn are independently normally distributed with expectation
θ and covariance matrix Σ˜. The most interesting case occurs if exact equivalence holds,
i.e. where θ = 0. In this case the power of the test ψδα (and hence asymptotically also of
its BCa bootstrap version) is given as
Pθ=0
(
√
n
||X||2p − 1
2
√
X ′ΣˆX
< uα
)
= Pθ=0
(
n||X||2p < n1/2uα2
√
X ′ΣˆX + n
)
.
Observe, that n||X||2p is distributed as
∑p
j=1 λ˜jU
2
j where λ˜j are the eigenvalues of Σ˜ and Uj
are i.i.d. standard normal r.v.’s. This is asymptotically a nondegenerate law whereas the
r.h.s. expression n1/2uα2
√
X ′ΣˆX = 2uα
√
(n1/2X)′Σˆ(n1/2X) is asymptotically distributed
as the square root of
∑p
j=1 ζjU
2
j with ζj being the eigenvalues of Σ˜
2 and the same r.v.’s
Uj as before. The resulting law is rather complicated and hence we suggest to simulate
the resulting power for given Σ˜ in order to obtain the required sample size. The case of
independent components is particularly simple and we give in Table 6 some values of the
required sample size in order to achieve a power of 0.8 and 0.9, respectively.
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dimension p σ2 = 0.25 σ2 = 0.5 σ2 = 1 σ2 = 2
p = 2 3(4) 6(8) 11(14) 20(26)
p = 3 4(5) 6(8) 13(16) 24(27)
Table 6: BCa-Bootstrap simulated sample sizes to achieve 0.8 (0.9) power for perfect
equivalence θ = 0 for two and three dimensions for various variances of the independent
univariate normal variables (300 bootstrap replications)
We mention finally, that the above formula can be generalized of course to the two sample
case, as treated in Theorem 4.2.
7 Conclusions
We have compared several tests for ellipsoidal hypothesis H : θ′Aθ ≥ ∆ versus K : θ′Aθ ≤
∆. It was shown that the BCa-bootstrap version of the test based on the statistic X
′AX
yields satisfactory results with respect to power and size. Even when this test is applied to
rectangular hypotheses its power comes close to the intersection union test (which is only
applicable for rectangular hypotheses), particularly as the dimension p of the parameter
θ increases. Moreover, the suggested BCa bootstrap test is very robust against violation
of the normality assumption of the error.
Finally we have proved asymptotic normality of the test statistic X ′AX and the validity
of the bootstrap principle for testing multivariate equivalence. This gives a theoretical
justification for recent approaches suggested for dissolution profile testing where a similar
test statistic was suggested and numerically investigated.
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